Bivalirudin versus heparin, without glycoprotein inhibition, in percutaneous coronary intervention: A comparison of ischemic and hemorrhagic outcomes over 10years.

Autor: Chaudry HI; Department of Internal Medicine, Dartmouth-Hitchcock Medical Center, Lebanon, NH, United States; Giesel School of Medicine at Dartmouth, Hanover, NH, United States. Electronic address: Hannah.Chaudry@lifespan.org., Curran TB; Giesel School of Medicine at Dartmouth, Hanover, NH, United States., Andrus BW; Giesel School of Medicine at Dartmouth, Hanover, NH, United States; Section of Cardiovascular Medicine, Heart and Vascular Center, Dartmouth-Hitchcock Medical Center, Lebanon, NH, United States., Conley SM; Giesel School of Medicine at Dartmouth, Hanover, NH, United States; Section of Cardiovascular Medicine, Heart and Vascular Center, Dartmouth-Hitchcock Medical Center, Lebanon, NH, United States., DeVries JT; Giesel School of Medicine at Dartmouth, Hanover, NH, United States; Section of Cardiovascular Medicine, Heart and Vascular Center, Dartmouth-Hitchcock Medical Center, Lebanon, NH, United States.

Publikováno v: Cardiovascular revascularization medicine : including molecular interventions [Cardiovasc Revasc Med] 2018 Apr - May; Vol. 19 (3 Pt B), pp. 338-342. Date of Electronic Publication: 2017 Sep 10.